HUTCHMED (China) Future Growth

Future criteria checks 4/6

HUTCHMED (China) is forecast to grow earnings and revenue by 47.9% and 18% per annum respectively. EPS is expected to grow by 105.7% per annum. Return on equity is forecast to be 8.9% in 3 years.

Key information

47.9%

Earnings growth rate

105.7%

EPS growth rate

Pharmaceuticals earnings growth21.6%
Revenue growth rate18.0%
Future return on equity8.9%
Analyst coverage

Good

Last updated22 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:H7T2 - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20269901166310618
12/31/202580837-301522
12/31/2024670-38-131-5822
6/30/2024611-42-65-47N/A
3/31/2024724296186N/A
12/31/2023838101187219N/A
9/30/20237983695133N/A
6/30/2023757-29248N/A
3/31/2023592-195-151-110N/A
12/31/2022426-361-305-269N/A
9/30/2022414-308-276-246N/A
6/30/2022401-255-246-223N/A
3/31/2022376-235-245-227N/A
12/31/2021356-195-221-204N/A
9/30/2021317-187-169-155N/A
6/30/2021279-178-118-105N/A
3/31/2021258-151-95-83N/A
12/31/2020228-126-70-62N/A
9/30/2020221-117-72-63N/A
6/30/2020209-110-88-79N/A
3/31/2020204-102-63-54N/A
12/31/2019205-106-89-81N/A
9/30/2019205-93-86-77N/A
6/30/2019214-87-52-44N/A
3/31/2019214-83-37-31N/A
12/31/2018214-75-39-33N/A
9/30/2018218-72-38-33N/A
6/30/2018217-61-51-47N/A
3/31/2018230-39N/A-49N/A
12/31/2017241-27N/A-9N/A
9/30/2017240-7N/A-4N/A
6/30/201723813N/A1N/A
3/31/201722712N/A-4N/A
12/31/201621612N/A-10N/A
9/30/201620038N/A2N/A
6/30/2016200-8N/A-1N/A
3/31/2016189-22N/A-5N/A
12/31/2015178-35N/A-9N/A
9/30/2015168-80N/A-11N/A
6/30/2015139-66N/A-6N/A
3/31/2015113-50N/A1N/A
12/31/201487-35N/A8N/A
9/30/201472-20N/A11N/A
6/30/2014597N/A21N/A
3/31/2014528N/A13N/A
12/31/20133726N/A5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: H7T2 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: H7T2 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: H7T2 is expected to become profitable in the next 3 years.

Revenue vs Market: H7T2's revenue (18% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: H7T2's revenue (18% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: H7T2's Return on Equity is forecast to be low in 3 years time (8.9%).


Discover growth companies